The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...

She's in bed waiting, and you can't track down where on your body that smell is coming from. Make sure you're clean for her ...

In a new brief report, researchers caution against repeating past mistakes in HIV prevention, as high drug prices and insurance coverage issues have slowed uptake of long-acting, bimonthly injectable ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

CVS Health, which runs the nation’s largest pharmacy benefit manager, will not cover Gilead Sciences’ FDA-approved HIV prevention drug Yeztugo, also known as lenacapavir, an injectable form of PrEP ...

The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an injectable form of the HIV prevention medication known as PrEP, marking a ...

The National Institute for Health and Care Excellence (NICE) has recommended cabotegravir (Apretude, ViiV Healthcare), an injectable form of preexposure prophylaxis (PrEP), marking a major milestone ...

We finally have the technology, infrastructure, and the political will to end the US HIV epidemic, write the Brown University doctors who lead the Rhode Island Public Health Institute. But access to ...

Sara Paparini has received funding from ViiV Healthcare and Gilead Sciences. Sophie Strachan receives funding from ViiV and Gilead and MSD she is affiliated with Sophia Forum Rosalie Hayes does not ...